what is the fda releasing with this? >> yeah. this is the fda's analysis of this data. let's put the numbers up and i'll talk you through this a little bit. i think this is important. when we look at the numbers in terms of how protective this vaccine is against moderate and severe disease, i can tell you these numbers are a little different from what we first heard from johnson & johnson and they're a little better. the south african variant circulating predominantly in south africa, previously it was thought to be 57% protective against moderate and severe disease. a little better now. kate, you can see there's the difference, the u.s. 72%, that's the coronavirus strain circulating here. in latin america, that's more likely the strain circulating in brazil and then the variant in south africa. there is a difference, and that's something to make note of in terms of how much of a difference these strains, how protective the vaccine will be. it was the bottom number to your question, 85% across the board globally where they said it's 85% protective against severe and cri

usually the fda follows their recommendations and we'd see the fda authorize this vaccine. but it the still not over. on sunday, the cdc advisory committee meets to give vaccine recommendations. that is the who, when, how is this all going to work with the vaccine. after that, another signoff from the cdc director and then that is when you're going to start seeing this distribution roll out, kate. >> and talk to me about the last bit, next week. assuming the vaccines are authorized for emergency use, how long before it is reasonable that shots are out and available? >> reporter: well, a lot of this will depend on the cdc advisory committee. right now we've been told by johnson & johnson, they've willing to put out the doses, but we're still awaiting what the advisory says, are they recommending certain communities or younger or older people and figure out how they're going to distribute to the groups following the guidelines of the cdc. but this is all still expected to happen next week. i've talked to multiple state officials are extremely excite and they're hearing they'r

>> the way this works is that we, the fda makes a recommendation to the fda. the fda considers that recommendation. then it goes to the centers for disease control and prevention through their committee, advisory committee for immunization practice, will determine are there specific groups that may best benefit from this vaccine? that will probably happen on sunday. by the middle of next week, probably by march 2nd or 3rd, this vaccine would start rolling off the shelves to the american public. >> what's your reaction, sanjay, to the major development in the fight against this virus? >> well, you know, it's been quite a year, right? a year ago, one year ago today, you know, we were talking about the beginning of this pandemic and the idea of a vaccine, let alone three. i don't think, really -- i don't think anybody sort of anticipated that we would move that quickly, that it could be done that quickly. so, it's really -- it's encouraging. you know, obviously there's been so much disspiriting news over this past year, wolf. the numbers on the right side of the

the fda has just now given the green light to pfizer to ship and store its coronavirus vaccine at warmer temperatures than previously required after the company submitted new data. that move is expected to have a significant impact on availability across the country. we're also following new developments in the congressional hearings on the deadly january 6th capitol siege. 50 days ago today, the acting u.s. capitol police chief telling angry lawmakers that the department did not follow protocols largely because officers were simply overwhelmed. she also warned that militia groups involved in the insurrection want to, quote, blow up the capitol. and president biden addresses a joints session of congress. also tonight, the annual conservative political action congress begins in orlando with the false claims about the 2020 election playing a prominent role on the agenda and those lies are still backed up by a sizable number of house and senate republicans. cnn spoke to some who are simply refusing to debunk those lies. let's begin with the disturbing new details emerging from today's heari

eliquis is fda-approved and has both. what's next? i'm on board. don't stop taking eliquis unless your doctor tells you to, as stopping increases your risk of having a stroke. eliquis can cause serious and in rare cases fatal bleeding. don't take eliquis if you have an artificial heart valve or abnormal bleeding. while taking eliquis, you may bruise more easily and it may take longer than usual for any bleeding to stop. seek immediate medical care for sudden signs of bleeding like unusual bruising. eliquis may increase your bleeding risk if you take certain medicines. tell your doctor about all planned medical or dental procedures. ask your doctor about eliquis. and if your ability to afford your medication has changed, we want to help. your grooming business is booming. you need to hire. i need indeed. indeed you do. the moment you sponsor a job on indeed you get a shortlist of quality candidates from a resume data base. claim your seventy-five-dollar credit when you post your first job at indeed.com/groomer >>> moments from now we're standing by

offit, that the fda is working now to put a plan in place to deal with the new variants. basically, as these variants become more dominant, and maybe vaccines not as effective against them, the fda is trying to put a system in place to handle that. what exactly wdoes that mean? what would they do or change going forward? >> here's when a line gets crossed. a line gets crossed when you have people who have received two doses of the vaccine that nonetheless are hospitalized with disease caused by one of these variants. that's when you know that we need that second generation of vaccine. the question is, how are you going to work on that second generation of vaccine in terms of allowing it to be used, say, through eua. and i think the more likely model will be the influenza model. where the vaccine would have to be tested to make sure that it's safe in a few hundred people and it induces the immune response you think it should induce to protect you. but you're not going to ask for another efficacy trial like the moderna trial of 30,000 people or the pfizer trial of 44,000 pe

the fda acknowledging for the first time that the vaccine is safe and effective against coronavirus, and data hinting it might prevent asymptomatic infections. fda officials meet friday to consider the emergency use authorization followed monday with the cdc, which means, this vaccine could be ready to roll out next week. johnson & johnson has pledged 20 million doses, but says it is prepared to immediately ship nearly 4 million doses as soon as it gets approved. today the white house says it's ready to go. >> while we await the fda's decision we want the american people to know that we're doing the work so that if the eua is granted we will waste no time getting this life-saving vaccine into the arms of americans. despite all of the temporary weather-related delays, our seven-day average daily doses administered is at 1.4 million. and we've already caught up on the weather-related shipping backlog. >> an emergency room condition and executive director of the committee to protect medicare. doctor davidson. g good to see you. could be roughly 4 million johnson & johnson vaccines shipp

first is the fda. it could pave the way for the first single-dose vaccine and the president's first landmark covid relief bill hitting a major setback hours before the house votes on it. want to brain better? unlike ordinary memory supplements— neuriva has clinically proven ingredients that fuel 5 indicators of brain performance. memory, focus, accuracy, learning, and concentration. try our new gummies for 30 days and see the difference. covid's still a threat. and on reopening schools, we know what happens when we don't put safety first. ignore proper ventilation or rates of community spread, and the virus worsens. fail to provide masks or class sizes that allow for social distancing, and classrooms close back down. a successful reopening requires real safety and accountability measures. including prioritizing vaccines for educators. parents and educators agree: reopen schools. putting safety first. to defend against dark forces attacking your organization, you need to see in the dark. to have the w

fda that this be approved. and we went through this same process with moderna and pfizer. so maybe even late friday we may hear that there's an authorized now emergency use authorization for the johnson & johnson vaccine. over the weekend, we will likely hear from the cdc committee that actually looks at these immunization protocols and they'll make the recommendations on the who, what, where. who should get this vaccine, where should it go, all that sort of stuff. and then i've talked to folks at johnson & johnson. there are a certain number of doses currently available. to your question, i guess, early next week they could probably be shipping out. >> two questions here, sanjay. one, i thought i had understood that from this data they were going to get some sign or at least ask about transmissibility, whether or not there was any indication about whether the johnson & johnson vaccine had an impact on transmissibility, whether you could get it and be asymptomatic. and also as we look at this data, it confirms

the fda set the meeting for their external scientific advisory panel for february 26th. they took the data review and a few days afterwards the cdc has to have their meeting and final review and recommendation. so i would guess it would be somewhere by the end of february if it gets authorized by the fda that it would have the green light to be distributed and the vaccination can start soon after that. maybe the first week of march. >> okay. let's talk about global phase 3 trial data, the j&j vaccine efficacy against moderate and severe diseases. that was 66%. 72% in the u.s. 85% effective in preventing hospitalizations. are those numbers good? >> the numbers are really good. if you look at the prevention of death, prevention of hospitalizations, no one died in this trial that got the vaccine. no hospitalizations. over 85% of the people were protected from that severe, most severe disease. didn't go to the hospital. that's really fantastic. the other numbers i wouldn't get too mixed up about. they're as good, i think, as the numbers we would see from the other vaccines i

of the data that fda scientists and physicians that determined that the vaccine need meets the fda's expectations for the safety and effectiveness, end quote. he's saying here that this authorization does give the fda's sign off that this is a safe vaccine. now, in the johnson & johnson trials, what has been found is that here are some of the common side effects. pain at the injection site, headache, fatigue, muscle pain. and serious adverse events were infrequent. there was one incident of anaphylactic reaction. pamela. >> thank you so much jacqueline howard. we appreciate it. by the way, we're awaiting a statement from the white house about this emergency authorization for the johnson & johnson vaccine. arlette saenz is in will ming son, delaware where the president and first lady are spending the remainder of the weekend. arlette, the biden administration is exceeding its goal of 100 million shots in 100 days. what does the addition of the new third vaccine mean? >> well, pamela, we actually just heard moments ago from president biden praising this new announcement as really this

once the fda makes its authorization we then are going to hear from the cdc. and tomorrow, an advisory committee to the cdc is going to meet and go over johnson & johnson's data and then the committee's going to make recommendations on how the vaccine can be used so the fda is first going to say, yes, it can be used if it's authorized for emergency use, but then the cdc advisory committee is going to recommend how it can be used. are there certain population groups that should be given priority access, for instance? and in the meantime we also have aware of what the distribution plans might look like. here's what the rollout could look like immediately. and the johnson & johnson says that it's going to have 3.9 million doses of vaccine right away, ready to be shipped out and sent to different locations. and within those 3.9 million we're going to see different allocations going to states. you see the numbers there. then we're going to see some going to community vaccination centers, for instance. and that's what the rollout will look like in the next few days

obviously the j&j will be putting their information into the fda for an app llication fo imagine use authorization. as these roll out, they will have different degrees of what is called point vaccine efficacy. so we know that we have a 72% overall efficacy in the united states for the j&j, but important to point out when people ask about the difference between 72% and 94%, 95% with the moderna and the pfizer is the fact that when you look at serious disease, hospitalizations and deaths, it is has had a profound effect on that. so as we get into the next weeks and months and more vaccines come out, there may be different -- they'll be common use of them in the big pool of vaccines not only for the united states but worldwide, but there may be some advantages that you might see with one versus the other. for example, the idea of a single dose, the lack of very strict cole chain as well as the availability of large number of doses. so i bring that to your attention. now dr. walensky talked about the variants and there is a difference between the vaccines that have been given in eua and

that's the sort of data that the fda is going to pay attention to. their bar for the emergency use authorization is do the benefits outweigh the risks? as simple as that. one other data point i want to show you, erica, because you and i have talked about this before. we know the vaccines protect against illness. it's been a long-standing question. do they help prevent you from getting inforgeted? what they found is people who received the vaccine were far less likely, 70% likely to have asymptomatic infection, so that kind of means that it seems to be protective to some extent against people actually carrying the virus. you remember, even if you're vaccinated you still have to wear a mask. why? you could be carrying the virus and spread it. this data seems to suggest that this should ultimately address that issue as well. >> which is exactly what we want to hear moving in that direction. there's also a new model that we've looked at so much over the last year or so, the new model showing cases and deaths are actually falling faster than expected. i k

know the national institute of health is encouraged by the finding, the fda is finding that it could lead to unforeseen consequences. back to that fda advisory committee that voted yesterday to recommend johnson & johnson's vaccine, one of the members really stressing the urgency of fighting the pandemic. and extremely hopeful that the availability of a third and single-dose vaccine will certainly boost some of the allotments that some of the states are receiving. in fact, victor had states could see stockpiles increase by 25%. certainly would be good news for those states trying to keep up. >> good news, indeed. polo sandoval, thank you so much. let's bring in public health specialist dr. saju mathew. you saw him there in polo's story. good morning. >> good morning. >> since it's lightly efficacy a little lower, should the johnson & johnson shot be reserved for people who are younger who generally don't get as severely ill? and then prioritize the moderna and pfizer shots for older, more vulnerable people? >> right. so, victor that debate is actually going on as you and i speak curr

here is what acting fda acting commissioner said in the announcement. she said the authorization of the vaccine expands the availability of vaccines, the best medical prevention method for covid-19, to help us in the fight against this pandemic. which as we all know has claimed over half a million lives here in the united states. and with the rollout of this johnson & johnson vaccine, we expect to see the initial rollout of vaccines this weekso week about 3.9 million dosing, expanding our capacity to vaccinate people by approximately 25%. this will add to the ability to get more vaccines out there. and it's exciting to see, pamela. >> it is. and it just means it's taking one huge step closer to more of a sense of normalcy in this country. jacqueline howard, dr. esther chu, thank you for coming on. >> thank you. >> and coming up next hour i'm going to talk to a 40-year-old covid long-hauler more than a year after his diagnosis. he says he is still dealing with agonizing chronic fatigue, pain and brain fog. ultra wideband,izon 5g the fastest 5g in the wor

the fda revealinusa single dose 85% effective against severe coronavirus. now, even more encouraging perhaps is the data hints that this vaccine may even prevent asymptomatic infection. j&j found after about nine weeks after the vaccine was given, it seemed 74% affective against asymptomatic infection. it doesn't just keep you from getting sick, but it may prevent you from getting sick at all. today the fda is confirming johnson & johnson has met the requirements to become the third u.s. vaccine to receive emergency use authorization. note, official authorization hasn't happened just yet. the white house says as soon as that comes through, millions of doses could be released next week. >> the governors are carefully planning their efforts and getting ready for the possible new vaccine. if authorized, we are ready to roll out this vaccine without delay. if an eua is issued, we anticipate allocating 3 to 4 million doses of johnson & johnson vaccine next week. >> also from the president's covid team, 25 million free washable face masks will soon be offered to

one, such as remdesivir has gained fda aproved. its effect is clear but modest. with regard to getting early intervention monoclonal antibodies, both from lile and regeneron have received emergency use authorization. here again the earlier one uses these the better. these are as efficient and more efficient in those individuals who don't necessarily have a good antibody response. the same can be said of convalescent plasma which has also earned an emergency use authorization. again, because of the variability in the tighter of anti-bodder and various plasma alliquots. the issue here is getting this as early as possible. there's been a number of trials of a variety of antivirals or other agents that are off the shelf that have not been targeted. i'll get to targeted intervention in just a moment and hyperimmune globulin is also in clinical trial, and we await results of all of these. with regard to therapeutics for advanced disease, as i mentioned that is generally aimed at blocking an aberrant inflammatory or immunologic response as well as other pathogenic mecha

cody misener, a member of that fda vaccine advisory committee. also with us, cnn's chief medical correspondent, dr. sanjay gupta. dr. misener, what questions do you still have? what do you need to see today? >> well, i think what's very important, alisyn, is that we need every tool we can possibly get to curtail the spread of this pandemic. as you know, thousands of americans are dying on a daily basis. so we need a safe and effective vaccine. and we need the more vaccines that become available, the better. >> there had been some concern, with any vaccine, there's always concerns with side effects or reactions, and bell's palsy had come up as an area of concern with the johnson & johnson vaccine. what are you looking for there? what questions do you need answered? >> bell's palasy is a neurologi issue that relates to movements of the face. it's a -- there's no increased association. the calculations have been carefully performed by the fda and there's no evidence of an increased risk at this time of bell's palsy following either moderna the pfize

and a major move by johnson & johnson in the battle against coronavirus, asking the fda for an emergency use authorization of its single shot covid-19 vaccine. so, as you can tell, we have a lot to talk about. i want to bring in cnn's white house correspondent mr. john harmon. congresswoman marjorie taylor greene officially removed from her assignments but only 11 republicans chose to hold her accountable. her last move to rewrite history did not work. where do you think this leaves the gop, john? >> the gop does not feel it can afford to aylienate people like mar marjorie taylor greene. -- energy, intensity, and turnout of a lot of blue collar voters, especially evangelicals, people in small towns and rural areas who feel alienated from the way american society is change. society is becoming more diverse, racially diverse, religiously diverse, less white, and they think the culture is passing them by, they think the economy is passing them by, and a lot of those people have turn in the recent years to more extreme political messages. we saw it during the obama years after the first blac

final authorization from the fda should come a bit later this week. a green light there would add millions more doses to the critical vaccine push. priority one now for a biden covid team that just moments ago gave a pandemic update. >> one of the most impactful things we can do is wear a mask. and this is so important during this critical period where cases are declining but variants that spread more easily are increasing throughout our country. >> awake and responsive. those are the words doctors in california now using to describe tiger woods this morning, that after lengthy surgery. the legendary golfer suffered open leg fracture after his car crossed onto the wrong side of a california road, smacked into a curb, then a tree and landed its side. back here in washington, more progress in getting key biden cabinet picks. the president's pick to lead the cia getting a confirmation hearing today. but another major personnel pick is being postponed. and the white house is scrambling this hour in hopes of avoiding its first capitol hill defeat. the budg

the fda said that the j & j vaccine is safe and effective. next a cdc estimate that always seems to predict more bad news is finally making a prediction in the other direction, now forecasting the pace o

and this comes as the fda now says the johnson & johnson single-dose covid vaccine is safe and effective and meets the requirements for emergency use authorization. that's expected to happen within a few days. the white house says 3 million, maybe even 4 million doses would be available to ship out next week. also breaking right now, the drugmaker moderna has just announced it's actually designed an updated version of its vaccine to help fight the south african virus variant. the company says doses have already been shipped to the national institutes of health for a clinical study. let's begin with all the late-breaking pandemic news unfolding right now. alexandra field is in new york city for us. alexandra, you're at a mass vaccination site in brooklyn. update our viewers. >> reporter: hey there, wolf. that declaration from the white house that the national emergency surrounding covid has been extended comes as no surprise given we're very much in the thick of a crisis. it also comes as we are seeing these new mass vaccination centers pop up around the country. this one here in brooklyn

once the fda makes its authorization we then are going to hear from the cdc. and tomorrow, an advisory committee to the cdc is going to meet and go over johnson & johnson's data and then the committee's going to make recommendations on how the vaccine can be used so the fda is first going to say, yes, it can be used if it's authorized for emergency use, but then the cdc advi

tomorrow an fda advisory panel expected to vote on a sheard vaccine. johnson & johnson the first single-dose option in the u.s. the cdc still needs to sign off giving the drugmaker emergency use authorization which could happen in days. j & j's vaccination will play a critical part in the biden administration's plight to get the vaccine into 100 million arms. >> today the president will deliver remarks to mark the, mark 50 million shots that have been administered since he entered office. he will also remind americans that now is not the time to let our guards down. especially in the face of new variants. >> those new variants include one just detected and spreading in new york city, which researchers say appears to evade the natural human immune response. much more on that in a moment. first to senior u.s. correspondent phil mattingly. the vice president is focusing on vaccinations today especially on the problem that communities of color or having them get the vaccine and hesitancy of wanting to get it. >> reporter: an enormous issue and one white ho

look, the fda advisory committee saying this was an easy decision. and really stressing the importance of trying to beat this pandemic. especially at this single-dose vaccine can meet increasing supplies throughout the country. >> every conceivable way to expand manufacturing of the vaccine. the third vaccine, to make even more rapid progress. >> reporter: with the nation, one critical step closer to distributing johnson & johnson's newly authorized vaccine a much needed decline in the nation's covid-19 cases and hospitalizations appears to be stalling. on friday, the head of the cdc warned the nation's seven-day average of cases is leveling out at about 66,000. that's a number that's still alarmingly high. that's a number that's still alarmingly high. >> we at cdc consider this a very concerning shift in the trajectory. >> reporter: adding to scientists' fears, the downward slope is ending, a rise in new virus variants threatening to reverse the progress. one such variant was detected in california and another in the northeast, likely having mutated

today an fda advisory committee will review the safety and efficacy of the vaccine. authorization could come as soon as this weekend. let's begin on capitol hill. cnn's lauren fox following the latest on the stimulus bill. first step, of course, in the house. then the senate. are they on schedule, right, for this to be passed before those enhanced unemployment benefits expire? >> well, they are right now, jim. they got a boost, if you will, from the senate parliamentarian last night who ruled they could not include the $15 minimum wage. while that was disappointing to a majority of democrats on capitol hill, it was good news for chuck schumer, the majority leader, who supports the minimum wage himself and had been pushing very hard for it behind the scenes. but he had some difficulties in his own caucus for moving that provision through the senate. essentially there were two democrats, joe manchin and senator kyrsten sinema of arizona who were opposed to including that $15 minimum wage increase in the underlying bill. this makes the job for schumer much easier, even

once the fda gives its green light, the process moves on to the cdc. moments ago the cdc director said she is ready and waiting to review what should become the third vaccine in the u.s. >> following the fda's actions, the advisory committee on immunization practices, or acip, meets to discuss in the advisory meeting. then acip will make recommendations for use of the vaccine and i will stand by ready to review them and sign. >> steve medical correspondent sanjay gupta is standing by to talk about this. sanjay, what are you expecting to see in the coming days? how fast will this new vaccine from johnson & johnson become available? >> it could happen very fast, brianna. we have some precedent on this because we saw this process play out with pfizer and moderna, you remember, and in those situations the advisory committee met and that evening or that day the fda actually approved that recommendation, so then you have an authorized vaccine. the cdc basically would meet to determine the who, how, when, meaning who is going to get this, how the vaccine is g

the fda told us, yes, it can be used with authorization, but the cdc is going to tell us how. in the meantime, here is the rollout plan. johnson & johnson has 3.9 million doses expected to be available immediately, according to the company, and among those doses, they will be allocated to state and local jurisdictions, retail pharmacies, federally qualified health centers and community vaccine centers. so that's the rollout we'll see in the next few days, but again, we first need to hear from the cdc on who this vaccine is recommended for. and then next we also are going to hear more discussions from the cdc today as this advisory committee panel continues around what the data tell us about the johnson & johnson vaccine. this vaccine was tested in about 44,000 people in the united states, latin america and south africa. here are some of those results. the global trials showed us that in the united states, the vaccine was found to be 72% efficacious. that means it was 72% protective against moderate and severe covid-19 in the trial. and then it was found to be 85% -- provided 8

i'll have more to say about this in the days after the fda review. look, we've been laser focused on the greatest operational challenge this country has ever undertaken. administering shots in the arms of hundreds of millions of americans. we're increasing the number of vaccinators. one we found was you may have the vaccine but not enough people to put the vaccine in someone's arm like you just saw. we brought back retired doctors and nurses. we already deployed more than 1,500 medical personnel you see during national disasters from the federal emergency management agency, fema. and we commissioned our commission corps from the department of health and human services and the defense department including the national guard supplying vaccinators. we're lining up thousands more to do the vaccinations. we're also setting up more places for people to get vaccinated. as of today, we provided $3.8 billion to states, territories, and tribes to create hundreds of new vaccination centers and ramp up the existing ones that are there already. we're working with

the fda analyzed this data and they're going to be reviewing it on friday. the right column there is critically important column. they find that after 28 days, there was a significant protection against severe disease. no hospitalizations at 28 days. there were two hospitalizations within the first 14 days which means that the protection from this vaccine seems to grow between two weeks to four weeks and sort of maxes out at around four weeks. so really that four-week mark after you get vaccinated is when you have the most protection. no deaths in the placebo -- no deaths in the vaccinated group as well. so this vaccine seems to be an effective vaccine. it seems to protect against what people care about the most, getting really sick, needing hospitalization and/or dying. >> you know, sanjay, that last point is so important. zero deaths in people that got this vaccine. and i say that because a lot of folks have come to me and said, well, if i have a choice, which vaccine should i get? i don't know if they're lucky enough to have a choice but there is some wor

today, when the fda says yes, the vaccine can be used under emergency use thoauthorization, tomorrow the cdc will tell us how it can be used. are there certain groups, for instance, that will be given priority access? an advisory committee to the cdc is going to make those recommendations tomorrow. then it will be up to cdc dr. ro rochelle walensky. johnson & johnson has up to 4 million doses ready to go, specifically 3.9 million doses. and among those doses, here is what the allocation will look like. about 2.8 million will go to states. 800,000, retail pharmacies. 90,000 will go to the federally qualified health centers. and then 70,000 will go to community vaccination centers. that's what we can expect to happen. but until the cdc gives its recommendation, we won't see shots going into arms quite yet. that's the next thing that we have to see take place. >> and then help folks understand the differences between the johnson & johnson vaccine and the pfizer/moderna versions that are already out there. >> reporter: yeah, there are some differences. i mean, johnson & johnson is given

the first and only fda approved combination of advil + acetaminophen. advil targets pain acetaminophen blocks it. new advil dual action fights pain for up to 8 hours. my body is truly powerful. i have the power to lower my a1c. because my body can still make its own insulin. and trulicity activates my body to release it, lowering my blood sugar from the first dose. once-weekly trulicity responds when my body needs it, 24/7. trulicity is for type 2 diabetes. it's not insulin. it isn't for people with type 1 diabetes. don't take trulicity if you're allergic to it, you or your family have medullary thyroid cancer, or have multiple endocrine neoplasia syndrome type 2. stop trulicity and call your doctor right away if you have an allergic reaction, a lump or swelling in your neck, severe stomach pain, changes in vision, or diabetic retinopathy. serious side effects may include pancreatitis. taking trulicity with sulfonylurea or insulin raises low blood sugar risk. side effects include indigestion, fatigue, belly pain, decreased appetite, nausea, diarrhea, an

we'll see if we can get that confirmed from the fda. but i think we'll be in a situation for a little while, realistically, where states won't be able to open up the vaccine to just anybody. but hopefully that's not too long away either. >> when you say a little while, not too long away, how long before the states open it up to everyone? >> i don't want to give a false sense of precision. we obviously model these things all the time. some of it is dependent on how quickly people want to sign up for vaccines. some of it is dependent on how quickly certain groups sign up for vaccines. in the spring, when things are opened up to more groups, if not to everybody, so we're talking about months, we're not talking about days or weeks. we're certainly not talking about the back half of the year. >> let's hope the johnson & johnson vaccine gets this emergency use authorization, because that's one shot as opposed to the two. pfizer says its vaccine can be stored in normal freezers up to two weeks. that would decrease reliance on those ultracold f

i don't want to get ahead of the fda, but if, in fact, that that is given to them, they're not going to have a lot of doses on the first day. it will likely be relatively few, which will then scale up a lot more. and it's just a matter of what happened with their production capability and how they are now going to be revving up. then soon after that they're going to have a lot of doses. but it's not going to be front loaded. >> i only have you for a couple more questions because our time is running out, but what should we expect from the vaccine makers in front of congress today? >> well, you know, i think that the vaccine makers are going to be people who have put a lot of effort into what they've done. and they're going to try to get as many doses to us as they possibly can. we now, as you know, have contractual relations with two of them for a total of 600 million doses for 300 million people which we likely will get as the president has said by july we'll have enough doses to do that, to vaccinate 300 million people with 600 million doses. so, hopefully we'll hear some positive n

we'll know in a few days whether or not the fda gives it sign off. i'm a little worried about that we may be confusing people on this variant if you will --. from what you understand from the columbia researchers, it hasn't been peer reviewed but it is a strong team looking at this. are they saying your bodies may not fight it off as well or vaccines like j&j, pfizer and moderna may not be able to fight it as well. >> there are concerns about both. one concern is that for people who have been vaccinated, if they were vaccinated against a little bit different formula of the virus, that the immunity may not work as well. on that point, for the vaccines that we have now from pfizer and moderna and also from the studies that we've seen of the j&j vaccine, it looks like there is still considerable protection. maybe not quite as good, especially against mild illnesses but very important protection, especially against more serious cases which is a main thing that we want to prevent in this whole pandemic. for people who have been previously infected with a

we're also watching an fda panel meeting right now. they're weighing whether to recommend the johnson & johnso

pfizer just received fda approval to store its covid-19 vaccine at normal freezer temperatures, making it easier to get doses in the arms of millions of americans. we're also following alarming new revelations about security failures during the january 6th insurrection. the acting capitol police chief telling angry lawmakers that her department did not follow emergency protocols during the riot and warned that groups want to, quote, blow up the capitol when president biden addresses a joint session of congress. this as conservative republicans are kicking off a big meeting in florida expected to indulge donald trump's false claims that he won the election. tonight a sizable number of gop lawmakers are telling cnn they see no reason to debunk the former president's lie. let's begin our coverage with our congressional correspondent ryan nobles covering today's house hearings on the capitol riots and security. lawmakers did not get the answers they clearly were hoping for. >> reporter: there is no question about that, wolf. this was the third hearing just this week on the topic of what we

president biden, you just heard, speaking just minutes after the fda, the advisers there recommended unanimously the authorization of the johnson & johnson single-dose covid-19 vaccine. it's another key hurdle toward making a third coronavirus vaccine available in the united states. and that should start as soon as the coming days, early next week. we have lots going on right now. i first want to go to our senior white house correspondent, phil mattingly. a very busy night, busy day for president biden. you heard him. update our viewers on what's going on? >> no question. just listening to wide ranging remarks that were equal parts hype man, cheerleader, and logistical coordinator. when it comes to the most important thing for the president and his team, trying to corral the coronavirus pandemic. the president sitting at a community vaccination center, at the houston texans stadium, where up to 6,000 shots a day are given out with the coronavirus vaccine. part of the logistical answer that the administration believes they're putting together, a wide-ranging scaled up version of the i

a day before the fda considered emergency authorization. an fda analysis provides strong protection against severe covid-19 and may reduce the spread of the virus by people who don't have symptoms. the fda also found the j&j vaccine may better protect against the south african variant. they are laser focused on all of the variants emerging including a new variant in new york city carrying mutations that may make vaccines less effective. variants are the most serious stumbling blocks that could reverse much of the progress being made. >> i think we spend a lot of time in wishful thinking over the last year. we could all wish for this to be the last lane but we wouldn't be doing our jobs if we weren't actively focused on containment or how might therapeutics help to minimize the effect of the variants, how might we make sure that if we do have another wave, it feels different? >> the johnson & johnson vaccine is a single shot so demand will be really high, but manufacturing got off to something of a slow start here. the company will only rele

the fda says another vaccine is safe. when will it get out to communities who need it? >> let's not let covid get us. let's get the vaccine instead, right? let's not let this thing get us. we know black people are disproportionately likely to contract the virus and die from it. for people living with h-i-v, keep being you. and ask your doctor about biktarvy. biktarvy is a complete, one-pill, once-a-day treatment used for h-i-v in certain adults. it's not a cure, but with one small pill, biktarvy fights h-i-v to help you get to and stay undetectable. that's when the amount of virus is so low it cannot be measured by a lab test. research shows people who take h-i-v treatment every day and get to and stay undetectable can no longer transmit h-i-v through sex. serious side effects can occur, including kidney problems and kidney failure. rare, life-threatening side effects include a buildup of lactic acid and liver problems. do not take biktarvy if you take dofetilide or rifampin. tell your doctor about all the medicines and supplements you take, if you are pregnant or breas

it's a big deal. >> the fda's vaccine advisers will meet tomorrow. they'll discuss whether to give the emergency approval to the j&j, as you call it, the johnson & johnson vaccine, which locks likely. it could begin rolling out as early as next week. how much is this single dose vaccine going to help us fight this virus? >> i think it's going to be very, very useful. first of all there are a lot of people who we can basically get a ahold of to vaccinate for people to come back for a second shot, people who have limited mobility, people who can make it to mass vaccination events but hard to schedule back for other events. this vaccine is going to give us a lot of flexibility. we'll also learn perhaps going forward some interesting new ideas about vaccina vaccination. there's some data that suggests that the pfizer vaccine, for instance, is superb bli effective at producing neutralizing antibodies after a single shot in people who have already had the infection. so, it may withbe that people w have recovered from the coronavirus, maybe they had it in t

that is being reviewed at the fda for the u.s. data. on february 26th, the fda will consult with their independent advisory committee, their verpac, and we should be hearing from them soon. with regard to astrazeneca and the no vax, they are fully enrolled. these are event-driven decisions, so when they reach certain events, they will look at the data and decide if they should go ahead with a request for a uea. now let me briefly address a question that is a very relevant question that we are now more commonly being asked. if you look at the existing trials, those have already gotten an eua, and those we anticipate and hope will get a uea, when will we say we can vaccinate children, children in the high school range and children in the elementary school range? you know from pfizer that they started off with a trial of 34,000 individuals down to 16-year-olds and then progressed it down to 12-year-olds. so what they're going to be doing in april, starting in april, they're going to be studying 12-year-olds down to 5 to 6-year-olds. that w

. >>> next, fda advisors giving the green light to another vaccine. and for this one, you only need one shot. >> we'll see in the second half of the year whether there will be a second dose recommendation for this vaccine. certainly one dose will cope you out of the hospital, the intensive care unit and out of the morgue. covid's still a threat. and on reopening schools, we know what happens when we don't put safety first. ignore proper ventilation or rates of community spread, and the virus worsens. fail to provide masks or class sizes that allow for social distancing, and classrooms close back down. a successful reopening requires real safety and accountability measures. including prioritizing vaccines for educators. parents and educators agree: reopen schools. putting safety first. fda advisors recommending authorization of the johnson & johnson's one-shot coronavirus vaccine. the fda could actually finalize emergency use authorization, get this, as early as tomorrow. and a member of the fda panel telling cnn we could actually see shots of the new

the first and only fda approved combination of advil + acetaminophen. advil targets pain acetaminophen blocks it. new advil dual action fights pain for up to 8 hours. >>> today georgia republican congresswoman managerry taylor greene declared the republican party, in her words, belongs to former president trump. former mayor of miami dade county, one of 11 republicans who voted yesterday to remove representative greene from her two committee assignments. congressman, thanks so much for joining us. she reacted earlier today. you probably heard this, but let me play it for our viewers. this is what she had to say about your vote and the vote of ten of your republican colleagues. >> when you have republicans in the ranks voting against one of their own, opening the door for democrats to go after every single republican next, that really is a big betrayal. and that could cost us the majority in '22. >> how do you respond, congressman? >> that's not going to cost us the majority in '22. the problem is the qanon, the rhetoric, the conspiracy theories. if you

friday, fda advisers recommended emergency use authorization for johnson & johnson's coronavirus vaccine and the fda expected to give it a green light at any moment and then it has to go to one last cdc committee. once this vaccine receives the final signoff, which could be this weekend, it will be the first single dose covid vaccine in the u.s. dean of tropical medicine here, dr. peter hotez. requires just a single dose and also evidence that suggests it may do more than just keep people from getting sick. it may actually prevent people from getting infected. what kind of impact might this vaccine have? >> yeah, and ana, also, this week in the new england journal of medicine, it was reported from israel that the pfizer biontech vaccine when given in two doses also seems to halt asymptomatic transmission. 92%. this is really game-changing news because what it means, you know, we've known that these vaccines are doing a great job of symptomatic transmission. with these vaccines, the point could be reached where if enough americans get vaccinated, we actually halt virus transmission. what

this is the vaccine the fda is considering right now. johnson & johnson, it's a single dose. against moderate and severe in terms of people who took this vaccine, 72% effective in the united states. less so in south africa and the u.k. where you have a variant. 85% effective in terms of no deaths. we bring in sanjay gupta. sanjay, number one, a successful vaccine. a single-dose vaccine, to get one dose and you're done, this would be a big help. >> yeah, and to help who may just have a hard time showing up for that second shot, john. some of the most vulnerable p.m. we -- people we've been talking about, people who are homeless, they don't have resources, live a transient lifestyle. so the one shot i think has more advantages. we know there are things the fda will be zeroing in as well, but that 85% number, that's a number that basically, no matter where you are in the world, whether variants are spreading or not, no deaths, no hospitalizations at 28 days, and 85% protective against severe death. one other piece of information, john, i'll share with you. i don't know if you sa

you're on the committee at the fda that will look at all the data, make a recommendation to the fda on authorization. dr. fauci told me last hour, people shouldn't get hung up on the slightly lower efficacy. first of all, do you agree? >> completely. the goal of this vaccine really is to keep you from visiting the doctor, keep you from going to the hospital and keep you from dying. and i think, you know, with the moderna vaccine and the pfizer vaccine, those vaccines were able to prevent mild infection, which is nice. but when you talk about having limited vaccines, here you have a johnson & johnson vaccine, at least from the press releases, it looks like it's good at preventing severe disease, which is what you want. people are scared of this virus. when they hear they have a vaccine that will keep them from being hospitalized or dying, that would be a desirous product. >> certainly would be. the j & j vaccine as it's called if it's authorized would you expect higher risk people should get priority for the moderna and pfizer vaccines and younger, lower risk people get the johnson & jo

february 26th the fda advisory committee will basically meet. that's a public meeting. anyone can watch that meeting. basically then they make a recommendation to the fda, the larger organization, about whether or not this should be authorized. and if it goes like it did with moderna and pfizer, that takes place rapidly. by the end of the month, early march, you would know from the fda if it's been authorized and then the cdc weighs in, as they did with the previous vaccines and say okay, this is the vaccine. who should get it? where should it go? within the next few weeks if it's going to be authorized that's probably when it's going to happen. >> once it's authorized that's good news. it will be another option for a lot of people who want to get a shot. what changes should be made, sanjay, to the vaccine manufacturing process to try to pick up the pace of it? >> i think there's three main things. in the beginning, wolf, you remember there was more vaccine that was distributed. the percentage on the right side of the screen was a much lower percentage. it was closer to

this is after the fda granted it authorization for emergency use. >> that vote is expected to happen this afternoon. once that is decided, the cdc director would give the final approval. >> nearly 4 million doses of that shot could begin rolling out to vaccine centers across the country as early as tomorrow. this will be the third coronavirus shot, remember, allowed to be administered in the u.s. so far, it's authorized for 18 years and up. >> it's a single-dose shot. it's not requiring any special storage. just ordinary refrigeration temperatures. that makes it easier to distribute across the country. the studies show it offers 86% protection against severe symptoms. >> paolo sandoval is outside a mass vaccination center in new york. we know the u.s. has fully vaccinated a little more than 7% of the population. what is the expectation this shot is really going to help elevate that number? >> reporter: putting it simply here, as pexperts have said, ths is a big, big deal. the emergency use authorization that has been issued here for a sul-dose vaccine, one that can be stored at norma